Drug development program started based on CAP® Human Cell Line

New platform may provide solutions for many RA-patients around the world

(PresseBox) ( Köln, )
Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The Netherlands) announce the start of Theraptech, a 2.4 million Euro therapeutic protein development program subsidized under the European Trans Bio Program. The major objective of the Theraptech project is to develop a recombinant human alkaline phosphatase (rhuAP) using the novel versatile human CAP® cell line, which has been shown to efficiently express glycosylated proteins. The rhuAP produced in CAP® cells is expected to feature improved pharmacokinetic and safety profile allowing for repeated dosing of alkaline phosphatase in chronic diseases. Based on a the anti-inflammatory mechanism of action of alkaline phosphatase towards e.g. TNFa, IL-6 and IL-8, as shown in both pre-clinical and clinical studies in acute conditions, we propose it to be developed as a therapeutic protein in major chronic diseases such as Rheumatoid Arthritis. The combined expertise of the members participating in the consortium covers the entire spectrum of activities needed to drive the project from molecular biology to GMP-production and recombinant product testing in preclinical and clinical trials, pushing towards a clinical phase II compliant product within the 3-year-time frame of the project.

Commenting on this unique co-operation, PharmaCell's CEO, Maurice Horsten, commented "Combining the strengths of our companies provides us with an excellent opportunity to build on PharmaCell's motto Humanizing Medicine® and to push this important project forward to the benefit of many patients around the world".

Cevec's CEO Dr Rainer Lichtenberger added: " CEVEC is excited about the strong scientific and commercial prospects of the Theraptech project. rhuAP will turn out to perfectly demonstrate the unique strengths of CEVEC's proprietary CAP® cell expression technology, in combination with the proven capabilities of our partners ".

On the scientific importance Alloksys' COO, Dr Ruud Brands commented: "rhuALP, based on the proposed mechanism of action in innate immune modulation, may enable the application in a wide array of disabling chronic inflammatory conditions, thereby eliminating the potentially adverse effects of currently marketed blockbuster products ".

About Alloksys Life Sciences BV - www.alloksys.eu

Alloksys Life Sciences BV, established in 2005 and located in Bunnik, The Netherlands is a biopharmaceutical company dedicated to the R&D of therapeutic proteins for the treatment of both acute and chronic inflammatory diseases. The lead phase II compound bIAP, an innate-immune system-modulating compound is developed for the indication: prevention of ischemia-reperfusion damage in invasive surgery. Chronic applications atherosclerosis, rheumatoid arthritis, Alzheimers and asthma are targeted. Alloksys established an integral research network comprising of several academic and biotech collaborations, both nationally and internationally. Partnerships with pharmaceutical companies for co-development of these indications are welcomed.

About PharmaCell - www.pharmacell.nl

PharmaCell provides contract services in the area of human cell & tissue banking & culturing as well as human cell line development and manufacturing of (bio) pharmaceuticals. Next to a GMP license, PharmaCell is the only commercial company in The Netherlands to hold an official license as Registered Tissue Establishment.

PharmaCell is also actively engaged in Research & Development work, both on behalf of some of its customers as well as in research consortia together with Universities, Academic Hospitals and other (bio)tech companies.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.